HeloisaPradoSoaresMD

Clinical Trials

• Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Start of enrollment: 2022 Mar 24

  Active, not recruiting

  Phase 3

  Roles: Contact

• Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE Start of enrollment: 2021 Dec 21

  Recruiting

  Phase 3

  Roles: Contact, Principal Investigator

• Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors Start of enrollment: 2022 May 05

  Recruiting

  Phase 2

• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease Start of enrollment: 2022 Mar 10

  Recruiting

  Phase 2, Phase 3

• Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer Start of enrollment: 2021 Mar 17

  Recruiting

  Phase 2

• Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors Start of enrollment: 2023 Aug 30

  Recruiting

  Phase 2

• Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET Start of enrollment: 2022 Dec 21

  Recruiting

  Phase 2

• Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors Start of enrollment: 2022 Mar 16

  Recruiting

  Phase 2

• Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study Start of enrollment: 2018 Jan 19

  Recruiting

  Phase 3

• Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial Start of enrollment: 2024 Jan 12

  Recruiting

  Phase 2

• Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors Start of enrollment: 2023 Feb 03

  Recruiting

  Phase 2

• Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung Start of enrollment: 2022 Jun 28

  Recruiting

  Phase 2, Phase 3

• Join now to see all